Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
292 hedge funds and large institutions have $4.54B invested in Intra-Cellular Therapies Inc. in 2023 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 122 increasing their positions, 89 reducing their positions, and 33 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 89
27% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 33
2% more funds holding
Funds holding: 287 → 292 (+5)
2% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $13M
15% less capital invested
Capital invested by funds: $5.34B → $4.54B (-$798M)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$61.3M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$58.3M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$46.7M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$35M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$53.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$37.3M |
| 3 |
PA
Perceptive Advisors
New York
|
-$15.6M |
| 4 |
Holocene Advisors
New York
|
-$15.3M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$14.4M |
ITCI Hedge Fund Activity: Q3 2023 in Review
292 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2023, worth a combined $4.54B — down 15% from $5.34B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ITCI positions and 33 closed out — a net gain of 9 holders — while 122 added to existing stakes and 89 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $61.3M. The largest seller was Hood River Capital Management, exiting entirely with an estimated $53.1M sold.
- 292 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2023, up from 287 in Q2 2023.
- Funds reported $4.54B of Intra-Cellular Therapies Inc. stock for Q3 2023, down 15% quarter-over-quarter.
- 42 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2023 and 33 closed out, a net change of +9 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2023 was Deep Track Capital, an estimated $61.3M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2023 was Hood River Capital Management, an estimated $53.1M sold.
Based on aggregated 13F filings for Q3 2023.